Differential expression of WISP1 in Asthma and COPD reveals unique molecular signatures

Christopoulou,M. E.,Papakonstantinou,E.,Stolz,D.
DOI: https://doi.org/10.1183/13993003.congress-2024.pa5294
IF: 24.3
2024-11-01
European Respiratory Journal
Abstract:Wnt-1 inducible signaling pathway protein 1 (WISP1), a target gene of the canonical Wnt/β-catenin pathway, plays a pivotal role in airway remodeling. However, the precise role of WISP1 and canonical Wnt/β-catenin pathway activation in asthma and COPD, remains unclear. This study investigated WISP1 expression differences in asthma and COPD. Endobronchial biopsies (EBB) from asthma (n=10) and COPD (n=10) patients were analyzed for WISP1 expression via immunohistochemistry, PCR and western blotting. Additionally, β-catenin localization was assessed by immunofluorescence. WISP1 expression was also assessed in primary airway smooth muscle cells (ASMCs) and fibroblasts established from EBB from asthma and COPD patients and associated with gene expression of p53, NRF2, NQO-1, GPX-1, IL-18, KIAA/CEMIP and p16 to evaluate the involvement of WISP1 in oxidative stress, inflammation, tissue remodeling and cellular senescence. Gene and protein expression of WISP1 were significantly higher in asthma EBB compared to COPD (p<0.05). These findings were validated in primary ASMC and fibroblasts. Asthma cells exhibited nuclear localization of β-catenin, indicating activation of the canonical Wnt/β-catenin pathway. In COPD cells, WISP1 levels inversely associated with p53, GPX1, p16 and NQO-1, while in asthma cells, a direct association of WISP1 levels with these genes was observed. Our study unveils distinct WISP1 expression patterns and activation of the canonical Wnt/β-catenin pathway in asthma and COPD, highlighting unique molecular signatures underlying these diseases and validating WISP1 as a potential clinical biomarker for further investigation.
respiratory system
What problem does this paper attempt to address?